These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36625591)

  • 1. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants.
    Qu P; Evans JP; Kurhade C; Zeng C; Zheng YM; Xu K; Shi PY; Xie X; Liu SL
    mBio; 2023 Feb; 14(1):e0317622. PubMed ID: 36625591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants.
    Qu P; Evans JP; Kurhade C; Zeng C; Zheng YM; Xu K; Shi PY; Xie X; Liu SL
    bioRxiv; 2022 Oct; ():. PubMed ID: 36299433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2.
    Hu B; Chan JF; Liu H; Liu Y; Chai Y; Shi J; Shuai H; Hou Y; Huang X; Yuen TT; Yoon C; Zhu T; Zhang J; Li W; Zhang AJ; Zhou J; Yuan S; Zhang BZ; Yuen KY; Chu H
    Emerg Microbes Infect; 2022 Dec; 11(1):2275-2287. PubMed ID: 36039901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.
    Katte RH; Ao Y; Xu W; Han Y; Zhong G; Ghimire D; Florence J; Tucker TA; Lu M
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
    Hossain A; Akter S; Rashid AA; Khair S; Alam ASMRU
    Microb Pathog; 2022 Sep; 170():105699. PubMed ID: 35944840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
    Xia S; Wang L; Jiao F; Yu X; Xu W; Huang Z; Li X; Wang Q; Zhu Y; Man Q; Jiang S; Lu L
    Emerg Microbes Infect; 2023 Dec; 12(1):2178241. PubMed ID: 36748716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
    Qu P; Evans JP; Faraone J; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    bioRxiv; 2022 Oct; ():. PubMed ID: 36299423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.
    Li Y; Shen Y; Zhang Y; Yan R
    Viruses; 2023 Jun; 15(6):. PubMed ID: 37376697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
    Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
    Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
    Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity.
    Kumar S; Delipan R; Chakraborty D; Kanjo K; Singh R; Singh N; Siddiqui S; Tyagi A; Jha V; Thakur KG; Pandey R; Varadarajan R; Ringe RP
    J Virol; 2023 Nov; 97(11):e0092223. PubMed ID: 37861334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of S2 mutations on Omicron SARS-CoV-2 cell surface expression and fusogenicity.
    Escalera A; Laporte M; Turner S; Karakus U; Gonzalez-Reiche AS; van de Guchte A; Farrugia K; Khalil Z; van Bakel H; Smith D; García-Sastre A; Aydillo T
    Emerg Microbes Infect; 2024 Dec; 13(1):2297553. PubMed ID: 38112266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity.
    Khatri R; Siddqui G; Sadhu S; Maithil V; Vishwakarma P; Lohiya B; Goswami A; Ahmed S; Awasthi A; Samal S
    Med Microbiol Immunol; 2023 Feb; 212(1):103-122. PubMed ID: 36583790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
    Pérez-Vargas J; Lemieux G; Thompson CAH; Désilets A; Ennis S; Gao G; Gordon DG; Schulz AL; Niikura M; Nabi IR; Krajden M; Boudreault PL; Leduc R; Jean F
    Antiviral Res; 2024 May; 225():105869. PubMed ID: 38548023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SARS-CoV-2 Spike is a virulence determinant and plays a major role on the attenuated phenotype of Omicron virus in a feline model of infection.
    Martins M; Nooruzzaman M; Cunningham JL; Ye C; Caserta LC; Jackson N; Martinez-Sobrido L; Fang Y; Diel DG
    J Virol; 2024 Mar; 98(3):e0190223. PubMed ID: 38421180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
    Tamura T; Yamasoba D; Oda Y; Ito J; Kamasaki T; Nao N; Hashimoto R; Fujioka Y; Suzuki R; Wang L; Ito H; Kashima Y; Kimura I; Kishimoto M; Tsuda M; Sawa H; Yoshimatsu K; Yamamoto Y; Nagamoto T; Kanamune J; Suzuki Y; Ohba Y; ; Yokota I; Matsuno K; Takayama K; Tanaka S; Sato K; Fukuhara T
    Commun Biol; 2023 Jul; 6(1):772. PubMed ID: 37488344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S:D614G and S:H655Y are gateway mutations that act epistatically to promote SARS-CoV-2 variant fitness.
    Yurkovetskiy L; Egri S; Kurhade C; Diaz-Salinas MA; Jaimes JA; Nyalile T; Xie X; Choudhary MC; Dauphin A; Li JZ; Munro JB; Shi PY; Shen K; Luban J
    bioRxiv; 2023 Apr; ():. PubMed ID: 37034621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).
    Chrysostomou AC; Vrancken B; Haralambous C; Alexandrou M; Gregoriou I; Ioannides M; Ioannou C; Kalakouta O; Karagiannis C; Marcou M; Masia C; Mendris M; Papastergiou P; Patsalis PC; Pieridou D; Shammas C; Stylianou DC; Zinieri B; Lemey P; The Comessar Network ; Kostrikis LG
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.